Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) reported RMB 21.34 billion (USD 3 billion) in H1 2022 revenue, up 25.88% year-on-year (YOY), and RMB 1.86 billion (USD 268.8 million) in net profits, up 18.57% YOY. Income from ex-China markets reached RMB 7.59 billion (USD 1 billion), accounting for 35.58% of total revenue.
R&D Investment
Fosun Pharma invested RMB 2.06 billion (USD 297.7 million) in R&D during H1, a 16.04% increase. Pharmaceutical R&D accounted for 14.39% of pharma business income, driving growth through new product launches.
New Product Performance
New products, including Comirnaty (COVID-19 vaccine), Hanlikang (rituximab), Hanquyou (trastuzumab), avatrombopag, and HaiSiZhuang (serplulimab), contributed over 25% of pharma revenues. Fosun Kite Biotechnology’s Yescarta (axicabtagene ciloleucel) was included in 44 provincial “Huiminbao” schemes and over 50 commercial insurance plans, with 100 registered treatment centers.
Licensing Deals
Fosun Pharma’s subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) licensed multiple products to Organon, Eurofarma, Getz Pharma, and others, leveraging its two-way licensing capabilities to maximize product value.-Fineline Info & Tech
